Graves’ Disease

ey0016.3-13 | Graves’ Disease | ESPEYB16

3.13. Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial

M Cole , AM Hynes , D Howel , L Hall , M Abinun , A Allahabadia , T Barrett , K Boelaert , AJ Drake , P Dimitri , J Kirk , N Zammitt , S Pearce , T Cheetham

To read the full abstract: BMJ Open. 2019;9:e024705.This protocol paper describes an innovative phase II trial to study the effect of a single low dose of adjuvant rituximab (a chimeric anti-B-cell monoclonal antibody targeting the surface molecule CD20) compared to classical carbimazole therapy in adolescents and young adults with Graves disease. Carbimazole treatment will be stop...

0 shares

ey0016.3-14 | Graves’ Disease | ESPEYB16

3.14. Long-term methimazole therapy in juvenile Graves' disease: a randomized trial

F Azizi , M Takyar , E Madreseh , A Amouzegar

To read the full abstract: Pediatrics. 2019;143(5).This randomized prospective long-term study investigated the effect of long-term (810 years) versus short-term (1824 months) methimazole therapy for Graves disease in 56 Iranian adolescents. The primary endpoint was disease remission at 48 months after stopping methimazole.The authors obs...

0 shares

ESPE Yearbook of Paediatric Endocrinology

Yearbook of Paediatric Endocrinology 2019

3. Thyroid

3.13. Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial

3.14. Long-term methimazole therapy in juvenile Graves' disease: a randomized trial

BiosciAbstracts